KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Emergent BioSolutions (EBS) over the last 16 years, with Q3 2025 value amounting to $23.4 million.

  • Emergent BioSolutions' Depreciation & Amortization (CF) fell 1136.36% to $23.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.3 million, marking a year-over-year decrease of 1254.45%. This contributed to the annual value of $108.8 million for FY2024, which is 1302.96% down from last year.
  • Per Emergent BioSolutions' latest filing, its Depreciation & Amortization (CF) stood at $23.4 million for Q3 2025, which was down 1136.36% from $23.5 million recorded in Q2 2025.
  • Emergent BioSolutions' Depreciation & Amortization (CF)'s 5-year high stood at $44.5 million during Q2 2022, with a 5-year trough of $23.4 million in Q3 2025.
  • Over the past 5 years, Emergent BioSolutions' median Depreciation & Amortization (CF) value was $29.2 million (recorded in 2021), while the average stood at $30.2 million.
  • As far as peak fluctuations go, Emergent BioSolutions' Depreciation & Amortization (CF) surged by 3403.61% in 2022, and later plummeted by 2606.74% in 2023.
  • Emergent BioSolutions' Depreciation & Amortization (CF) (Quarter) stood at $29.2 million in 2021, then rose by 22.26% to $35.7 million in 2022, then dropped by 17.09% to $29.6 million in 2023, then fell by 12.16% to $26.0 million in 2024, then dropped by 10.0% to $23.4 million in 2025.
  • Its last three reported values are $23.4 million in Q3 2025, $23.5 million for Q2 2025, and $25.4 million during Q1 2025.